IMRX · Company research
Immuneering Corporation Class A Common Stock (IMRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| PETS,TPL,AYI,VKTX,IMRX,BBSI,TRON,NRXS,KFY | Stock Prices | Quote Comparison - Yahoo Finance - Yahoo! Finance Canada | PETS,TPL,AYI,VKTX,IMRX,BBSI,TRON,NRXS,KFY | Stock Prices | Quote Comparison - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| AYI,PETS,VKTX,TPL,IMRX,BBSI,TRON,NRXS,KFY | Stock Prices | Quote Comparison - Yahoo! Finance Canada | AYI,PETS,VKTX,TPL,IMRX,BBSI,TRON,NRXS,KFY | Stock Prices | Quote Comparison Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 12, 2026 | neutral | 0 | 0.6 |
| Immuneering Corporation (IMRX) stock price, news, quote and history - Yahoo Finance Australia | Immuneering Corporation (IMRX) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 3, 2026 | neutral | 0 | 0.6 |
| Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | Immuneering Corporation announced preclinical data demonstrating that atebimetinib, a MEK inhibitor, enhances PD-1 checkpoint blockade in RAS mutant tumor models. The findings support the company's plans to conduct a Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer patients. The poster will be presented at the SITC 41st Annual Meeting in November 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | Immuneering Corporation announced preclinical data demonstrating that atebimetinib, a MEK inhibitor, enhances PD-1 checkpoint blockade in RAS mutant tumor models. The findings support the company's plans to conduct a Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer patients. The poster will be presented at the SITC 41st Annual Meeting in November 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| A pancreatic cancer drug combination is in a late-stage study. Its trial plan will be shown in Madrid. - Stock Titan | A pancreatic cancer drug combination is in a late-stage study. Its trial plan will be shown in Madrid. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| 84% of evaluable pancreatic cancer patients kept or gained weight after three months - Stock Titan | 84% of evaluable pancreatic cancer patients kept or gained weight after three months Stock Titan | View source ↗ | Stock Titan | Sep 10, 2026 | neutral | 0 | 0.6 |
| Price-Driven Insight from (IMRX) for Rule-Based Strategy - Stock Traders Daily | Price-Driven Insight from (IMRX) for Rule-Based Strategy Stock Traders Daily | View source ↗ | Stock Traders Daily | Sep 8, 2026 | neutral | 0 | 0.6 |
| Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Eastern Progress | Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know Eastern Progress | View source ↗ | Eastern Progress | Sep 5, 2026 | neutral | 0 | 0.6 |
| Understanding the Setup: (IMRX) and Scalable Risk - Stock Traders Daily | Understanding the Setup: (IMRX) and Scalable Risk Stock Traders Daily | View source ↗ | Stock Traders Daily | Aug 27, 2026 | neutral | 0 | 0.6 |
| FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan | FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option Stock Titan | View source ↗ | Stock Titan | Aug 26, 2026 | neutral | 0 | 0.6 |
| Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution' - Seeking Alpha | Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution' Seeking Alpha | View source ↗ | Seeking Alpha | Jul 27, 2026 | neutral | 0 | 0.6 |
| Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance | Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Jul 15, 2026 | neutral | 0 | 0.6 |
| Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com | Cantor Fitzgerald initiates Immuneering stock with overweight rating Investing.com | View source ↗ | Investing.com | Jul 8, 2026 | neutral | 0 | 0.6 |
| Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - Simply Wall Street | Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth Simply Wall Street | View source ↗ | Simply Wall Street | Jun 30, 2026 | neutral | 0 | 0.6 |
| IMRX Forecast — Price Target — Prediction for 2027 - TradingView | IMRX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits | IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? Stocktwits | View source ↗ | Stocktwits | Jun 1, 2026 | neutral | 0 | 0.6 |
| $IMRX stock is up 13% today. Here's what we see in our data. - Quiver Quantitative | $IMRX stock is up 13% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | May 29, 2026 | neutral | 0 | 0.6 |
| $IMRX stock is up 31% today. Here's what we see in our data. - Quiver Quantitative | $IMRX stock is up 31% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | May 22, 2026 | neutral | 0 | 0.6 |
| Immuneering Corporation: Updates Inbound At The End Of The Month (NASDAQ:IMRX) - Seeking Alpha | Immuneering Corporation: Updates Inbound At The End Of The Month (NASDAQ:IMRX) Seeking Alpha | View source ↗ | Seeking Alpha | May 12, 2026 | neutral | 0 | 0.6 |
| Immuneering Corporation Class A Common Stock (IMRX) Stock Price: Oct 8 Close $3.74 - Gotrade | Immuneering Corporation Class A Common Stock (IMRX) Stock Price: Oct 8 Close $3.74 Gotrade | View source ↗ | Gotrade | Feb 3, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.